abrdn plc Buys 26,597 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

abrdn plc raised its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 6.2% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 457,695 shares of the biotechnology company's stock after buying an additional 26,597 shares during the quarter. abrdn plc owned about 0.48% of Sarepta Therapeutics worth $55,294,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Simplify Asset Management Inc. boosted its holdings in shares of Sarepta Therapeutics by 84.6% during the third quarter. Simplify Asset Management Inc. now owns 193,010 shares of the biotechnology company's stock worth $24,105,000 after purchasing an additional 88,474 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Sarepta Therapeutics by 2.7% during the third quarter. Geode Capital Management LLC now owns 1,696,354 shares of the biotechnology company's stock worth $211,910,000 after purchasing an additional 44,306 shares during the last quarter. Summit Partners Public Asset Management LLC boosted its holdings in shares of Sarepta Therapeutics by 547.9% during the third quarter. Summit Partners Public Asset Management LLC now owns 138,118 shares of the biotechnology company's stock worth $17,250,000 after purchasing an additional 116,800 shares during the last quarter. Larson Financial Group LLC boosted its holdings in shares of Sarepta Therapeutics by 1,649.8% during the third quarter. Larson Financial Group LLC now owns 8,749 shares of the biotechnology company's stock worth $1,093,000 after purchasing an additional 8,249 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its holdings in shares of Sarepta Therapeutics by 30.1% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 78,244 shares of the biotechnology company's stock worth $9,772,000 after purchasing an additional 18,095 shares during the last quarter. Institutional investors and hedge funds own 86.68% of the company's stock.

Sarepta Therapeutics Trading Down 0.3 %

NASDAQ SRPT traded down $0.29 on Friday, hitting $111.82. 881,445 shares of the stock were exchanged, compared to its average volume of 847,020. The company's 50-day moving average price is $121.12 and its two-hundred day moving average price is $125.96. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. Sarepta Therapeutics, Inc. has a 52-week low of $102.15 and a 52-week high of $173.25. The company has a market capitalization of $10.68 billion, a price-to-earnings ratio of 89.46 and a beta of 0.75.

Insider Activity

In other Sarepta Therapeutics news, Director Kathryn Jean Boor sold 1,636 shares of the stock in a transaction on Thursday, December 5th. The shares were sold at an average price of $125.55, for a total transaction of $205,399.80. Following the transaction, the director now directly owns 5,880 shares of the company's stock, valued at $738,234. This represents a 21.77 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the transaction, the director now directly owns 22,840 shares in the company, valued at $2,851,345.60. The trade was a 31.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.70% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on SRPT. Cantor Fitzgerald upgraded Sarepta Therapeutics from a "neutral" rating to an "overweight" rating and raised their price objective for the stock from $152.00 to $167.00 in a report on Thursday, November 7th. Guggenheim raised their price objective on Sarepta Therapeutics from $148.00 to $150.00 and gave the company a "buy" rating in a research report on Thursday, November 7th. Robert W. Baird lowered their target price on Sarepta Therapeutics from $200.00 to $193.00 and set an "outperform" rating for the company in a research note on Thursday, November 7th. Needham & Company LLC restated a "buy" rating and set a $202.00 target price on shares of Sarepta Therapeutics in a research note on Monday, January 27th. Finally, Piper Sandler lowered their target price on Sarepta Therapeutics from $200.00 to $182.00 and set an "overweight" rating for the company in a research note on Wednesday, November 27th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $178.71.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.